BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Barclays Healthcare Conference in Miami, FL on Tuesday, March 15 th at 10:15 a.m. ET . Management's remarks will be accessible live through Vertex's website at
-In Australia, approximately 1,000 people with CF ages 12 and older have two copies of the F508del mutation- -ORKAMBI reimbursement process already underway in Australia - LONDON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Therapeutic Goods
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced it has awarded the company's 2016 Cystic Fibrosis (CF) Circle of Care grants , totaling approximately $1 million, to 18 non-profit medical, academic, patient and community organizations.
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that it will present at the Leerink Healthcare Conference in New York, NY on Thursday, February 11 th at 11:10 a.m. ET . Vertex will also present at the Cowen Healthcare Conference in Boston, MA on Tuesday,
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for the use of KALYDECO ® (ivacaftor) in people with cystic
-Full-year 2015 total non-GAAP revenues of $1.01 billion , including net product revenues of $351 million for ORKAMBI ® (lumacaftor/ivacaftor) and $632 million for KALYDECO ® (ivacaftor) in cystic fibrosis- -Vertex reiterates 2016 financial guidance for KALYDECO net product revenues of $670 to $690
-Approximately 1,500 people in Canada are ages 12 and older and have two copies of the F508del mutation, the most common genetic form of the disease- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has approved Pr ORKAMBI ®
-Approximately 25,000 people with cystic fibrosis worldwide currently eligible for treatment with ORKAMBI ® (lumacaftor/ivacaftor) or KALYDECO ® (ivacaftor); Vertex advancing the development of multiple medicines with the goal of treating all people with cystic fibrosis- -Fourth quarter 2015 net
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 34 th Annual J.P. Morgan Healthcare Conference on Monday, January 11 at 12:30 p.m. ET ( 9:30 a.m. PT ).
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Piper Jaffray Healthcare Conference in New York on Tuesday, December 1 at 11:00 a.m. ET . Management's remarks will be available live through
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Michael J. Parini to the role of Executive Vice President and Chief Legal Officer. Mr. Parini will serve as a member of Vertex's Executive Committee, reporting directly to Jeffrey Leiden
-In Europe, approximately 12,000 people with CF ages 12 and older have two copies of the F508del mutation- -Positive CHMP Opinion was received in September 2015 - -Country-by-country reimbursement process will now begin- LONDON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)
- European Commission approves expanded use of ivacaftor in children with cystic fibrosis ages 2 to 5 who have one of 9 gating mutations; approximately 125 children ages 2 to 5 have one of the approved gating mutations in Europe - - European Commission approves expanded use of ivacaftor in people
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 10 th at 11:30 a.m. ET . Management's remarks will be available live through Vertex's website at www.vrtx.com in
-Third quarter 2015 revenues of $310 million , including net product revenues of $131 million for ORKAMBI ® (lumacaftor/ivacaftor) and $166 million for KALYDECO ® (ivacaftor) in cystic fibrosis- -Vertex increases guidance for 2015 KALYDECO net revenues; now expects KALYDECO revenues of $605 to $620
-Gene editing technology to be used to discover treatments to address the mutations and genes known to cause and contribute to cystic fibrosis- -Vertex and CRISPR to utilize gene editing approach to discover treatments for genetic diseases, including sickle cell disease- -Companies establish
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2015 financial results on Wednesday, October 28, 2015 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .
-Two next-generation correctors to enter clinical development in November; studies of a triple combination of a next-generation corrector with VX-661/ivacaftor planned for 2016 in people with CF- -Treating the underlying cause of CF with ORKAMBI ® (lumacaftor/ivacaftor) or KALYDECO ® (ivacaftor)
-More than 1,500 people with CF are ages two and older and have one of these 23 residual function mutations in the U.S.- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a
-CHMP recommends Marketing Authorization for lumacaftor in combination with ivacaftor for people with cystic fibrosis ages 12 and older with two copies of the F508del mutation- -CHMP recommends Marketing Authorization for ivacaftor for children with cystic fibrosis ages 2 to 5 with 9 gating
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Morgan Stanley Healthcare Conference in New York, NY on Wednesday, September 16 th at 11:40 a.m. ET .
Hosts August 19 th back to school event with Bottom Line for 200+ first-generation college students BOSTON --(BUSINESS WIRE)-- Vertex and the University of Massachusetts (UMass) today announced the recipients of the annual Vertex Science Leaders Scholarship , a four-year scholarship to pursue their
-Second quarter 2015 total revenues of $166 million , including net product revenues of approximately $155 million for KALYDECO ® (ivacaftor) in cystic fibrosis- -Vertex increases guidance for total 2015 KALYDECO net revenues; now expects KALYDECO revenues of $575 to $590 million - -ORKAMBI™
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2015 financial results on Wednesday, July 29, 2015 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .
-Approximately 8,500 people in the U.S. are ages 12 and older and have two copies of the F508del mutation, the most common genetic form of the disease- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S.
-Approximately 8,500 people in the U.S. are ages 12 and older and have two copies of the F508del mutation, the most common genetic form of the disease- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S.
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Sangeeta N. Bhatia , M.D., Ph.D., joined its board of directors as an independent director. Dr. Bhatia was elected to serve a three-year term ending in 2018. " Dr.
-Analysis from TRAFFIC and TRANSPORT extension study of lumacaftor in combination with ivacaftor showed that improvements in lung function and other measures of disease were maintained through 48 weeks in people with cystic fibrosis who have two copies of the F508del mutation- BRUSSELS --(BUSINESS
-ENaC inhibition aims to restore or improve hydration of cell surfaces in the lungs to improve lung function- -Parion to receive $80 million up-front payment with potential for additional development and regulatory milestones and royalty payments- BOSTON & DURHAM, N.C.
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Goldman Sachs Healthcare Conference in Rancho Palos Verdes, CA on Thursday, June 11 th at 12:20 p.m. ET ( 9:20 a.m. PT ).
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the New England Journal of Medicine (NEJM) published data from the two Phase 3 studies of ORKAMBI TM (lumacaftor/ivacaftor), an investigational medicine designed to treat the underlying cause of
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jeffrey Leiden , M.D., Ph.D., Chairman, President & CEO of Vertex will present at the UBS Healthcare Conference in New York, NY on Tuesday, May 19 th at 11:00 a.m. ET .
- FDA decision expected by July 5, 2015 PDUFA date- -Approximately 8,500 people with cystic fibrosis in the U.S. have two copies of the F508del mutation and are ages 12 and older- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S.
-First quarter 2015 total revenues of $139 million , including net product revenues of $130 million for KALYDECO ® (ivacaftor) in cystic fibrosis- -Cash, cash equivalents and marketable securities of approximately $1.2 billion on March 31, 2015 - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2015 financial results on Wednesday, April 29, 2015 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .
-The combination was generally well tolerated and all patients completed 12 weeks of treatment- -Mean within-group absolute improvement from baseline in lung function of 4.4 (p=0.009) and 3.0 (p=0.026) percentage points at week 4 and through 12 weeks of treatment, respectively, in patients who
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) approved KALYDECO ® for use in children ages 2 to 5 with cystic fibrosis (CF) who have one of 10 mutations in the cystic fibrosis transmembrane conductance
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the RBC Capital Market Healthcare Conference in New York, NY on Tuesday, February 24 th at 11:30 a.m. ET . Vertex will also present at the Cowen and Company Healthcare Conference in
-Full-year 2014 total revenues of $580 million , including net product revenues of $464 million for KALYDECO in cystic fibrosis- -Cash, cash equivalents and marketable securities of approximately $1.4 billion on December 31, 2014 - -Company expects total 2015 KALYDECO net revenues of $560 to $580
-Priority Review granted for combination of lumacaftor and ivacaftor in people with cystic fibrosis ages 12 and older who have two copies of the F508del mutation; PDUFA date of July 5, 2015 - -More than 3,700 people with CF expected to be eligible to receive KALYDECO by end of 2015 supporting
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 33 rd Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 12:30 p.m. ET ( 9:30 a.m. PT ).
--Approximately 500 people with cystic fibrosis ages 6 and older have the R117H mutation in the United States -- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated today announced that David Altshuler , M.D., Ph.D., will join the company as Executive Vice President, Global Research and Chief Scientific Officer. Dr. Altshuler was one of the four founding members of the Broad Institute of Harvard
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Deutsche Bank BioFEST in Boston on December 2 at 8:45 a.m. ET . Management's remarks can be accessed live through Vertex's website at www.vrtx.com
-U.S. submission includes request for Priority Review; Accelerated Assessment has been granted in the EU- -Approximately 8,500 people in the U.S. and 12,000 in Europe ages 12 and older have two copies of the F508del mutation- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Credit Suisse Healthcare Conference on Tuesday, November 11 at 12:00 p.m. ET . Management's remarks can be accessed live through Vertex's website at www.vrtx.com in the
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended September 30, 2014 . Vertex reported total third quarter 2014 GAAP revenues of $179 million , including revenues of $127 million from KALYDECO ®
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration's Pulmonary Allergy Drugs Advisory Committee (PADAC) voted 13-2 to recommend approval of KALYDECO ® (ivacaftor) in people with cystic fibrosis (CF) ages 6 and
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2014 financial results on Tuesday, October 28, 2014 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .
-Data from across Vertex's cystic fibrosis research and development programs to be presented at the 28 th Annual North American Cystic Fibrosis Conference (NACFC) beginning today- -Interim analysis of rollover study following the Phase 3 TRAFFIC and TRANSPORT studies showed sustained improvements
